• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贫血管理:快速通道贫血和静脉铁治疗服务的开发。

Anemia management: development of a rapidaccess anemia and intravenous iron service.

机构信息

Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.

出版信息

Risk Manag Healthc Policy. 2013 Aug 6;6:13-22. doi: 10.2147/RMHP.S41818. eCollection 2013.

DOI:10.2147/RMHP.S41818
PMID:23950666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3741173/
Abstract

This article describes the initiation and evolution of the Rapid-Access Anemia Clinic (RAAC) at Guy's and St Thomas' Hospitals, London, UK. This clinic was set up to provide diagnosis and treatment, and to coordinate investigative procedures, where necessary, into the underlying causes of anemia. Initially piloted with anemic preoperative orthopedic patients, the clinic now treats a wide range of conditions, deriving from both internal and external referrals. Treatment includes dietary advice, supplementation with iron, vitamin B12 and folate, and blood transfusion. Most patients at the RAAC need iron replacement, the majority of which require intravenous (IV) iron. Therefore the first-line IV iron-administration protocol is carefully considered to ensure viability of the service and patient satisfaction. Four IV irons available in the UK are discussed, with explanation of the benefits and drawbacks of each product and the reasoning behind the IV iron choice at different stages of the RAAC's development. Costs to the service, affected by IV iron price and administration regimen, are considered, as well as the product's contraindications. Finally, the authors reflect on the success of the RAAC and how it has improved patients' quality-of-treatment experience, in addition to benefiting the hospital and National Health Service in achieving specific health-care mandates and directives. Drawing from the authors' experiences, recommendations are given to assist others in setting up and providing a successful rapid-access anemia service or similar facility.

摘要

本文描述了英国伦敦盖伊和圣托马斯医院快速贫血门诊 (RAAC) 的启动和发展。该诊所的设立旨在提供诊断和治疗,并在必要时协调对贫血根本原因的调查程序。该诊所最初针对贫血的骨科术前患者进行试点,现在治疗范围广泛,包括来自内部和外部转诊的各种疾病。治疗包括饮食建议、铁、维生素 B12 和叶酸补充剂以及输血。RAAC 的大多数患者需要补铁,其中大多数需要静脉 (IV) 补铁。因此,仔细考虑了一线 IV 铁给药方案,以确保服务的可行性和患者满意度。讨论了英国可用的四种 IV 铁,解释了每种产品的优缺点以及在 RAAC 发展的不同阶段选择 IV 铁的原因。考虑了对服务的成本影响,包括 IV 铁价格和管理方案,以及产品的禁忌症。最后,作者反思了 RAAC 的成功之处,以及它如何改善患者的治疗体验质量,此外还使医院和国民保健服务受益于实现特定的医疗保健任务和指令。作者根据自己的经验提出了一些建议,以帮助其他人设立和提供成功的快速贫血服务或类似设施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/eaae99a44b68/rmhp-6-013Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/f0fa3dd05570/rmhp-6-013Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/3d31e1b48c42/rmhp-6-013Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/eaae99a44b68/rmhp-6-013Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/f0fa3dd05570/rmhp-6-013Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/3d31e1b48c42/rmhp-6-013Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65d5/3741173/eaae99a44b68/rmhp-6-013Fig3.jpg

相似文献

1
Anemia management: development of a rapidaccess anemia and intravenous iron service.贫血管理:快速通道贫血和静脉铁治疗服务的开发。
Risk Manag Healthc Policy. 2013 Aug 6;6:13-22. doi: 10.2147/RMHP.S41818. eCollection 2013.
2
Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.爱尔兰术前缺铁性贫血治疗诊所资源影响模型的开发。
Adv Ther. 2020 Mar;37(3):1218-1232. doi: 10.1007/s12325-020-01241-0. Epub 2020 Feb 6.
3
Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice.新的静脉用铁剂在医院应用后成本最小化的对比分析更新。
Ther Clin Risk Manag. 2011;7:501-9. doi: 10.2147/TCRM.S25882. Epub 2011 Dec 12.
4
An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.一项在英国贫血诊所中对两种不同静脉铁制剂的卫生服务效率和患者体验的分析。
J Med Econ. 2013;16(1):108-14. doi: 10.3111/13696998.2012.731458. Epub 2012 Oct 10.
5
[Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].[静脉补铁在慢性肾脏病中的应用:益处、局限性及优化实践的建议]
Nephrol Ther. 2015 Dec;11(7):531-42. doi: 10.1016/j.nephro.2015.04.009. Epub 2015 Oct 20.
6
Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.静脉补铁与口服补铁治疗 CKD 贫血的疗效比较:一项更新的系统评价和荟萃分析。
Am J Kidney Dis. 2016 Nov;68(5):677-690. doi: 10.1053/j.ajkd.2016.04.018. Epub 2016 Jun 16.
7
A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000.基于医院的成本最小化研究:介绍异麦芽糖铁 1000 对英国医疗保健系统潜在的财务影响。
Ther Clin Risk Manag. 2011;7:103-13. doi: 10.2147/TCRM.S17536. Epub 2011 Mar 15.
8
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia.羧基麦芽糖铁可减少结肠癌合并贫血患者的输血次数及住院时间。
Int J Colorectal Dis. 2016 Mar;31(3):543-51. doi: 10.1007/s00384-015-2461-x. Epub 2015 Dec 22.
9
A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.一项针对英国缺铁性贫血治疗中铁异麦芽糖与羧基麦芽糖铁的患者水平成本效益分析。
J Med Econ. 2020 Jul;23(7):751-759. doi: 10.1080/13696998.2020.1745535. Epub 2020 May 1.
10
Hepcidin as a potential predictor for preoperative anemia treatment with intravenous iron-A retrospective pilot study.铁调素作为预测术前贫血采用静脉铁剂治疗的潜在标志物:一项回顾性的初步研究。
PLoS One. 2018 Aug 8;13(8):e0201153. doi: 10.1371/journal.pone.0201153. eCollection 2018.

引用本文的文献

1
Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease: A Case Series.镰状细胞病中的迟发性溶血性输血反应:病例系列。
Am J Case Rep. 2022 Jan 5;23:e934681. doi: 10.12659/AJCR.934681.
2
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults.英国胃肠病学会成人缺铁性贫血管理指南。
Gut. 2021 Nov;70(11):2030-2051. doi: 10.1136/gutjnl-2021-325210. Epub 2021 Sep 8.
3
The exclusion of hypochromia from the iron deficiency screen.缺铁筛查中低色素血症的排除。

本文引用的文献

1
Comparative efficacy of three forms of parenteral iron.三种肠外铁剂的比较疗效
J Blood Transfus. 2012;2012:473514. doi: 10.1155/2012/473514. Epub 2011 Nov 22.
2
Prevalence of maternal anaemia and its predictors: a multi-centre study.孕产妇贫血患病率及其预测因素:一项多中心研究。
Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):99-105. doi: 10.1016/j.ejogrb.2011.07.041. Epub 2011 Sep 3.
3
Anaemia is highly prevalent among unselected internal medicine inpatients and is associated with increased mortality, earlier readmission and more prolonged hospital stay: an observational retrospective cohort study.
Risk Manag Healthc Policy. 2014 Mar 14;7:61-3. doi: 10.2147/RMHP.S53668. eCollection 2014.
贫血症在内科住院患者中普遍存在,且与死亡率增加、更早再次入院和更长的住院时间相关:一项观察性回顾性队列研究。
Intern Med J. 2012 Jun;42(6):683-91. doi: 10.1111/j.1445-5994.2011.02566.x.
4
Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease.炎症性肠病患儿、青少年和成人贫血的患病率及处理。
Inflamm Bowel Dis. 2012 Mar;18(3):513-9. doi: 10.1002/ibd.21740. Epub 2011 May 20.
5
Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations.在基层医疗环境中治疗慢性肾脏病贫血:心血管结局与管理建议
Osteopath Med Prim Care. 2007 Oct 2;1:14. doi: 10.1186/1750-4732-1-14.
6
Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.老年透析前慢性肾脏病患者未治疗贫血的医疗费用。
J Am Soc Nephrol. 2006 Dec;17(12):3497-502. doi: 10.1681/ASN.2006030289. Epub 2006 Nov 2.
7
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET.新发贫血对慢性心力衰竭患者发病率和死亡率的影响:COMET研究结果
Eur Heart J. 2006 Jun;27(12):1440-6. doi: 10.1093/eurheartj/ehl012. Epub 2006 May 22.